Familial hypercholesterolaemia (FH) is a common autosomal semi-dominant and highly
penetrant disorder of the low-density lipoprotein (LDL) receptor pathway, characterised by …

Familial hypercholesterolemia (FH) poses a global health challenge due to high incidence
rates and underdiagnosis, leading to increased risks of early-onset atherosclerosis and …

Purpose Gene selection for genomic newborn screening (gNBS) underpins the validity,
acceptability, and ethical application of this technology. Existing gNBS gene lists are highly …

Summary Background Homozygous familial hypercholesterolaemia (HoFH) is a rare
inherited disorder characterised by extremely high concentrations of LDL cholesterol …

FH confers a significant risk for ASCVD from a young age. Achieving better medication
adherence is foundational for improving clinical outcomes and reducing the burden of …

Globalization is putting many countries' social cohesion under strain (Daboul, 2022). People
are growing increasingly frustrated with healthcare providers' inability to provide levels of …

Background and aims Familial hypercholesterolemia (FH) is becoming a global burden.
However, it remains underdiagnosed and undertreated worldwide. This study aimed to …

The clinical outcome for children and adolescents with homozygous familial
hypercholesterolaemia (HoFH) can be devastating, and treatment options are limited in the …

Background and Objectives: The proprotein convertase subtilisin-kexin type 9 (PCSK9)
inhibitors evolocumab and alirocumab are recently developed promising drugs used for …

Homozygous familial hypercholesterolaemia (HoFH) is a rare but devastating disease with
high morbidity and mortality commencing in early childhood. 1 The primary clinical goal for …